Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis-Reference-Cited by-同舟云学术

Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis

Published:2022-08 Issue: Volume:148 Page:135-145
ISSN:0895-4356
Container-title:Journal of Clinical Epidemiology
language:en
Short-container-title:Journal of Clinical Epidemiology

Author:

Hauser Anthony^ORCID,Goldstein Fardo,Reichmuth Martina L.,Kouyos Roger D.,Wandeler Gilles,Egger Matthias,Riou Julien

Funder

National Institutes of Health

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Publisher

Elsevier BV

Subject

Epidemiology

Reference51 articles.

1. UNAIDS. Ending the AIDS epidemic by 2030.

2. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy;Bacheler;Antimicrob Agents Chemother,2000

3. Bridging the gap between HIV epidemiology and antiretroviral resistance evolution: Modelling the spread of resistance in South Africa;Hauser;PLOS Comput Biol,2019

4. Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine southern African countries: a modelling study;Riou;BMC Infect Dis,2021

5. World Health Organization (WHO). HIV drug resistance report 2017 [Internet]. 2017 [cited 2020 Nov 19]. Available from:https://www.who.int/hiv/pub/drugresistance/hivdr-report-2017/en/.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A National HIV Provider Survey of Antiretroviral Therapy Preferences for Management of Treatment-Naive and Experienced Individuals With Drug Resistance;Open Forum Infectious Diseases;2023-10-31

2. Current ART, determinants for virologic failure and implications for HIV drug resistance: an umbrella review;AIDS Research and Therapy;2023-10-27

3. Raltegravir Plus Nucleoside Reverse-Transcriptase Inhibitor (NRTI) Plus Lopinavir, NRTIs Plus Lopinavir for Second-Line Treatment of HIV: 96-Week Follow-up Results from a Randomized Controlled Trial;J BIOL REG HOMEOS AG;2023

4. Roadmap for Achieving Universal Antiretroviral Treatment;Annual Review of Pharmacology and Toxicology;2023-01-20

5. Research Progress on Influencing Factors of AIDS Curative Effect;Advances in Clinical Medicine;2023